# Vaccine Therapy in Treating Patients With Advanced Melanoma

> **NCT00705640** · PHASE1 · COMPLETED · sponsor: **Craig L Slingluff, Jr** · enrollment: 45 (actual)

## Conditions studied

- Intraocular Melanoma
- Malignant Conjunctival Neoplasm
- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** multi-epitope melanoma peptide vaccine
- **BIOLOGICAL:** tetanus toxoid helper peptide
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT00705640
- **Lead sponsor:** Craig L Slingluff, Jr
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-06
- **Final completion:** —
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2016-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00705640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00705640, "Vaccine Therapy in Treating Patients With Advanced Melanoma". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00705640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*